Eric Batard1,2, Nathalie Lecadet3, Nicolas Goffinet3, Jean-Benoit Hardouin4, Didier Lepelletier5,6, Gilles Potel3,5, Emmanuel Montassier3,5. 1. Emergency Department, Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, 1 place Alexis-Ricordeau, 44000, Nantes, France. eric.batard@univ-nantes.fr. 2. Faculté de Médecine and Pharmacie, Université de Nantes, EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, 1 rue Gaston-Veil, 44000, Nantes, France. eric.batard@univ-nantes.fr. 3. Emergency Department, Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, 1 place Alexis-Ricordeau, 44000, Nantes, France. 4. Faculté de Médecine and Pharmacie, Université de Nantes, EA 4275 SPHERE Biostatistics Pharmacoepidemiology and Human Science Research Team, 1 rue Gaston-Veil, 44000, Nantes, France. 5. Faculté de Médecine and Pharmacie, Université de Nantes, EA 3826 Thérapeutiques Cliniques et Expérimentales des Infections, 1 rue Gaston-Veil, 44000, Nantes, France. 6. Department of Microbiology and Infection Control, Centre Hospitalier Universitaire de Nantes, Hôtel-Dieu, 1 place Alexis-Ricordeau, 44000, Nantes, France.
Abstract
OBJECTIVE: Fluoroquinolones and 3rd-generation cephalosporins that are prescribed for pneumonia may be avoided and replaced by a penicillin in some cases. We aimed to determine if the proportion of patients treated for pneumonia with a cephalosporin, a fluoroquinolone or both varies among Emergency Departments (EDs), and to estimate the proportion of avoidable prescriptions. METHODS: This was a retrospective study of patients treated for pneumonia in eight French EDs, and subsequently hospitalized in non-ICU wards. Third-generation cephalosporins or respiratory fluoroquinolones were presumed unavoidable if they met both criteria: (1) age ≥65 years or comorbid condition; and (2) allergy or intolerance to penicillin, or failure of penicillin, or previous treatment with penicillin, or for fluoroquinolones only, suspected legionellosis. RESULTS: We included 832 patients. Thirty-four percent (95 % CI, 31-38 %) of patients were treated with a cephalosporin, a respiratory fluoroquinolone or both (range among EDs 19-44 %). Four EDs were independent risk factors for prescription of a cephalosporin, a fluoroquinolone or both [adjusted OR, 2.27 (1.64-3.15)], as were immune compromise [aOR 2.54 (1.56-4.14)], antibacterial therapy started before arrival in the ED [aOR 3.32 (2.30-4.81)], REA-ICU class III or IV [aOR 1.93 (1.15-3.23)], PSI class V [aOR 1.49 (1.00-2.20)], fluid resuscitation [aOR 3.98 (2.49-6.43)] and non-invasive ventilation in the ED [aOR, 7.18 (1.7-50.1)]. Treatment with a cephalosporin, a fluoroquinolone or both was avoidable in 67 % (62-73 %) of patients. CONCLUSION: Cephalosporins and fluoroquinolones use in pneumonia is highly variable among EDs. The majority of these prescriptions are avoidable. Antibiotic stewardship programs should be implemented to restrict their use in EDs.
OBJECTIVE:Fluoroquinolones and 3rd-generation cephalosporins that are prescribed for pneumonia may be avoided and replaced by a penicillin in some cases. We aimed to determine if the proportion of patients treated for pneumonia with a cephalosporin, a fluoroquinolone or both varies among Emergency Departments (EDs), and to estimate the proportion of avoidable prescriptions. METHODS: This was a retrospective study of patients treated for pneumonia in eight French EDs, and subsequently hospitalized in non-ICU wards. Third-generation cephalosporins or respiratory fluoroquinolones were presumed unavoidable if they met both criteria: (1) age ≥65 years or comorbid condition; and (2) allergy or intolerance to penicillin, or failure of penicillin, or previous treatment with penicillin, or for fluoroquinolones only, suspected legionellosis. RESULTS: We included 832 patients. Thirty-four percent (95 % CI, 31-38 %) of patients were treated with a cephalosporin, a respiratory fluoroquinolone or both (range among EDs 19-44 %). Four EDs were independent risk factors for prescription of a cephalosporin, a fluoroquinolone or both [adjusted OR, 2.27 (1.64-3.15)], as were immune compromise [aOR 2.54 (1.56-4.14)], antibacterial therapy started before arrival in the ED [aOR 3.32 (2.30-4.81)], REA-ICU class III or IV [aOR 1.93 (1.15-3.23)], PSI class V [aOR 1.49 (1.00-2.20)], fluid resuscitation [aOR 3.98 (2.49-6.43)] and non-invasive ventilation in the ED [aOR, 7.18 (1.7-50.1)]. Treatment with a cephalosporin, a fluoroquinolone or both was avoidable in 67 % (62-73 %) of patients. CONCLUSION:Cephalosporins and fluoroquinolones use in pneumonia is highly variable among EDs. The majority of these prescriptions are avoidable. Antibiotic stewardship programs should be implemented to restrict their use in EDs.
Authors: Roger Sordé; Vicenç Falcó; Michael Lowak; Eva Domingo; Adelaida Ferrer; Joaquin Burgos; Mireia Puig; Evelyn Cabral; Oscar Len; Albert Pahissa Journal: Arch Intern Med Date: 2010-09-27
Authors: M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij Journal: Clin Microbiol Infect Date: 2011-11 Impact factor: 8.067
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: Jesús Rodríguez-Baño; Juan C Alcalá; Jose M Cisneros; Fabio Grill; Antonio Oliver; Juan P Horcajada; Teresa Tórtola; Beatriz Mirelis; Gemma Navarro; María Cuenca; María Esteve; Carmen Peña; Ana C Llanos; Rafael Cantón; Alvaro Pascual Journal: Arch Intern Med Date: 2008-09-22
Authors: Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper Journal: Clin Infect Dis Date: 2011-03-01 Impact factor: 9.079
Authors: Mamoon A Aldeyab; Stephan Harbarth; Nathalie Vernaz; Mary P Kearney; Michael G Scott; Feras W Darwish Elhajji; Motasem A Aldiab; James C McElnay Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335
Authors: M F Engel; M van Velzen; A I M Hoepelman; S Thijsen; J J Oosterheert Journal: Eur J Clin Microbiol Infect Dis Date: 2012-10-31 Impact factor: 3.267
Authors: Katherine M Shea; Athena L V Hobbs; Theresa C Jaso; Jack D Bissett; Christopher M Cruz; Elizabeth T Douglass; Kevin W Garey Journal: Antimicrob Agents Chemother Date: 2017-05-24 Impact factor: 5.191